Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Frequently asked questions
What sector does Edgewise Therapeutics Inc (EWTX) operate in?
Edgewise Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Edgewise Therapeutics Inc (EWTX) current stock price?
As of the latest data, Edgewise Therapeutics Inc stock price is $39.17, with a previous close of $39.31. Edgewise Therapeutics Inc lost -$0.14 in the last trading session, representing a -0.36% loss.
What is Edgewise Therapeutics Inc (EWTX) current market capitalization?
Edgewise Therapeutics Inc market cap is approximately 4.25 billion.
What is Edgewise Therapeutics Inc (EWTX) Earnings Per Share (EPS)?
The trailing EPS is -$1.86, and the forward EPS is -$1.82.
What is Edgewise Therapeutics Inc (EWTX) EBITDA?
Edgewise Therapeutics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -56.73 million.
Does Edgewise Therapeutics Inc (EWTX) pay dividends?
No. Edgewise Therapeutics Inc does not pay a dividend.
When is Edgewise Therapeutics Inc (EWTX) next earnings report?
Edgewise Therapeutics Inc is expected to release its next earnings report on September 30, 2026.
What is Edgewise Therapeutics Inc (EWTX) beta (volatility) score?
Edgewise Therapeutics Inc has a beta of 0.355, indicating lower volatility than the overall market.
